What’s the typical price of cilostazol 100 mg in the Philippines?
Prices for cilostazol 100 mg vary widely by pharmacy (and by whether the brand or generic is being sold), but the most reliable way to check the current local price is to compare listings on Philippine online pharmacies and in-store promotions, since cilostazol is often sold as a generic (and stock can change by outlet).
If you tell me your city (or which online pharmacy you prefer), I can help you narrow down what to look for (brand vs generic, tablet count per strip/box), and how to compare the real “per tablet” cost.
Cilostazol 100 mg brand vs generic: does it change the price?
In the Philippines, cilostazol is commonly available as both brand-name and generic versions. Generic tablets usually cost less, but the final price depends on:
- manufacturer/brand
- pack size (number of tablets per box)
- pharmacy markups and discounts
- current supply and promotions
How to compare prices correctly (per tablet vs per box)
Because listings may show different pack sizes, compare the unit cost:
- Find the total price of the package.
- Divide by the number of tablets in the box/strip.
That gives the best apples-to-apples comparison if one pharmacy sells (for example) 30 tablets vs another sells 60 tablets.
Is there a cheaper alternative if cilostazol 100 mg is expensive?
If the goal is to treat the same condition, alternatives usually depend on your prescriber’s diagnosis (for example, peripheral arterial disease vs off-label use). The most common cost-saving approach is often switching to a lower-cost generic with the same strength (100 mg), but any substitution should follow your doctor or pharmacist’s advice.
Can patents or “official” pricing affect cilostazol prices here?
Cilostazol is an older medicine, so pricing in the Philippines is generally driven more by market competition (generic availability) than by patent exclusivity. If you want, share the exact product name and box size you’re looking at, and I’ll help you interpret whether it’s the same strength/formulation across listings.
Sources: None provided in the prompt (no DrugPatentWatch.com or other references were given).